X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs GLENMARK PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD GLENMARK PHARMA BIOCON LTD/
GLENMARK PHARMA
 
P/E (TTM) x 92.6 26.3 352.5% View Chart
P/BV x 7.8 4.1 190.8% View Chart
Dividend Yield % 0.1 0.3 50.3%  

Financials

 BIOCON LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
GLENMARK PHARMA
Mar-17
BIOCON LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188993 119.6%   
Low Rs305729 41.8%   
Sales per share (Unadj.) Rs68.7325.5 21.1%  
Earnings per share (Unadj.) Rs7.639.3 19.2%  
Cash flow per share (Unadj.) Rs14.048.7 28.7%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.2 57.7%  
Book value per share (Unadj.) Rs86.3159.2 54.2%  
Shares outstanding (eoy) m600.00282.17 212.6%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.92.6 410.6%   
Avg P/E ratio x98.921.9 451.1%  
P/CF ratio (eoy) x53.417.7 302.0%  
Price / Book Value ratio x8.65.4 159.8%  
Dividend payout %13.25.1 260.2%   
Avg Mkt Cap Rs m447,900242,991 184.3%   
No. of employees `0006.113.0 47.4%   
Total wages/salary Rs m9,31116,408 56.7%   
Avg. sales/employee Rs Th6,705.87,083.9 94.7%   
Avg. wages/employee Rs Th1,514.21,265.4 119.7%   
Avg. net profit/employee Rs Th736.9855.1 86.2%   
INCOME DATA
Net Sales Rs m41,23491,857 44.9%  
Other income Rs m2,062374 551.9%   
Total revenues Rs m43,29692,230 46.9%   
Gross profit Rs m8,29120,367 40.7%  
Depreciation Rs m3,8512,644 145.7%   
Interest Rs m6152,373 25.9%   
Profit before tax Rs m5,88715,724 37.4%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,5693,827 41.0%   
Profit after tax Rs m4,53111,088 40.9%  
Gross profit margin %20.122.2 90.7%  
Effective tax rate %26.724.3 109.5%   
Net profit margin %11.012.1 91.0%  
BALANCE SHEET DATA
Current assets Rs m41,48668,746 60.3%   
Current liabilities Rs m21,41327,027 79.2%   
Net working cap to sales %48.745.4 107.2%  
Current ratio x1.92.5 76.2%  
Inventory Days Days6485 75.2%  
Debtors Days Days9496 98.6%  
Net fixed assets Rs m50,66124,132 209.9%   
Share capital Rs m3,000282 1,063.1%   
"Free" reserves Rs m48,80844,643 109.3%   
Net worth Rs m51,80844,925 115.3%   
Long term debt Rs m17,89845,363 39.5%   
Total assets Rs m99,897117,639 84.9%  
Interest coverage x10.67.6 138.6%   
Debt to equity ratio x0.31.0 34.2%  
Sales to assets ratio x0.40.8 52.9%   
Return on assets %5.211.4 45.0%  
Return on equity %8.724.7 35.4%  
Return on capital %9.619.1 50.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05856,152 21.5%   
Fx outflow Rs m7,3488,084 90.9%   
Net fx Rs m4,71048,068 9.8%   
CASH FLOW
From Operations Rs m6,6216,574 100.7%  
From Investments Rs m-6,840-7,124 96.0%  
From Financial Activity Rs m-2,3975,432 -44.1%  
Net Cashflow Rs m-2,6121,992 -131.1%  

Share Holding

Indian Promoters % 40.4 48.3 83.6%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 6.9 121.7%  
FIIs % 10.7 34.4 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 56,727 193.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   PIRAMAL ENTERPRISES  GSK PHARMA  DR. DATSONS LABS  DR. REDDYS LAB  NOVARTIS  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, BOB-Vijaya-Dena Merger, and Top Stocks in Action Today(Pre-Open)

Share markets in India continued their momentum and ended in red yesterday. Sectoral indices traded in red, with stocks in the realty sector, power sector and PSU sector leading the losses.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS